Cytori Therapeutics, Inc. (CYTX)

[KennyPro]

Likely so but a PPS of between 3-5 bucks is not out of the question in time. JMHO but I think they will manage to turn this boat around and clean up the mess.

[hopester]

$10.75? Pie in the sky!
Check the sell ratings on it.
These analysts, by way of their conflicting views and changes, HAVE NOT A CLUE.

[A. SPEER]

$cytx price target 10.75$
https://weekherald.com/2019/01/15/brokerages-set-cytori-therapeutics-inc-cytx-target-price-at-10-75.html

[A. SPEER]

$cytx price target $10.75

https://weekherald.com/2019/01/15/brokerages-set-cytori-therapeutics-inc-cytx-target-price-at-10-75.html

[A. SPEER]

$cytx upgraded by zack
https://www.fairfieldcurrent.com/news/2019/01/18/cytori-therapeutics-cytx-upgraded-at-zacks-investment-research.html/amp?__twitter_impression=true

[A. SPEER]

$cytx filings
https://www.finanznachrichten.de/nachrichten-aktien/cytori-therapeutics-inc.htm

[KennyPro]

Bid and volume slowly rising. I hope that keeps up!

[KennyPro]

Nice volume today. Great to see some interest coming in here.

[Paulness]

NEWS -- San Diego Jan 8, 2019 (Thomson StreetEvents) -- Edited Transcript of Cytori Therapeutics Inc earnings conference call or presentation Wednesday, November 14, 2018 at 10:30:00pm GMT

https://finance.yahoo.com/news/week-ahead-biotech-conferences-pdufa-202708364.html

[cabir]

And? No more aktiv here?!!

[cabir]

NEWS??!!!??

[rktmn]

So why no rise in price per share??

One would have thought at least .40

[halbroke1]

CYTX $$$$ MEGA-HUGE NEWS TODAY...WOW !!!...CRAZY THIN...WAS TRADING AT $20.00/SHARE, WILL SURPASS IT THIS TIME..."GROSSLY UNDERVALUED".

[rktmn]

"ALLLLLLL ABBOOOAAARRDDD"

Just bought in for first time!!!!

Looks like this is going to be a great ride!!!!!!

[Paulness]

NEWS -- Cytori Announces Japan Class III Medical Device Approval for Cell Therapy Product

Date: 12/03/2018 @ 7:30AM

Cytori Therapeutics (NASDAQ: CYTX) (“Cytori” or the “Company”) today announced that the Company has received approval for the Celution Cell Therapy System consumable bundle in Japan as a Class III medical device. The Class III designation will allow Cytori to expand its current commercial efforts in Japan and provides a clear framework for future expanded regulatory claims and reimbursement under the November 2014 PMD Act.

Furthermore, Cytori announced today that the Company has successfully outsourced an important assembly portion of the production process for its Celution Cell Therapy consumables from San Diego, CA to Viant Medical in San Antonio, Texas. The first consumable lots following this new process were shipped to customers in November 2018.

“Obtaining Class III designation follows many months of constructive interaction with the Japanese Ministry of Health, Labour and Welfare following the approval of the 2014 PMD Act,” said Marc H. Hedrick, MD, President and Chief Executive Officer of Cytori Therapeutics. “This approval coupled with the outsourced production allows Cytori to meet forecasted product demand, particularly in Japan, and better prepares us for the data read out in our Japan ADRESU pivotal trial next year.”

In Japan, Class III and Class IV medical devices require the highest levels of safety and efficacy data In Japan. These devices are also required to have special controls. Other such examples of Class III medical devices include: hemodialysis equipment, artificial bones and joints, mechanical ventilation apparatus, and balloon catheters.

Cytori currently has a fully functional logistics, sales and marketing team in Japan dedicated to commercialization of the Celution Cell Therapy System. Cytori is forecasting double digit growth in consumable utilization in Japan for 2018. Prior to the class III approval, Cytori has been selling the Celution technology mostly for aesthetic and orthopedic indications under a Class I designation.

ADRESU is an investigator-initiated, multicenter, 45 patient, open-label, single arm clinical trial of Cytori’s ECCI-50 cellular therapeutic, comprised of Celution®-prepared autologous Adipose Derived Regenerative Cells (ADRCs) and Adipose Cells for men with stress urinary incontinence as a complication of prostate intervention. A total of 45 patients, all treated in Japan, were enrolled in this potential approval trial. One-year data readout from ADRESU is anticipated in the first half of 2019.

The ADRESU trial was based on a promising pilot trial with short-term data of 11 patients published in the International Journal of Urology in 2014 and long-term data of 14 patients presented at the International Continence Society in 2017, which “demonstrated that transurethral injection of autologous ADRCs can be a safe and effective treatment modality for postprostatectomy incontinence”. Details of the ADRESU protocol and trial can be found on BMC Urology, clinicaltrials.gov and the University Hospital Medical Information Network website.

The primary endpoint for the ADRESU trial is the percentage of patients who experience greater than 50% reduction in urinary leakage volume from baseline (as measured by the weight of unintended urinary leakage over 24 hours) at 52 weeks after treatment. A number of other key secondary endpoints are also being assessed. If the primary endpoint is successfully achieved, the data may be used to seek approval of ECCI-50 for this indication.

The trial costs are substantially supported by the Japan Agency for Medical Research and Development, an independent administrative agency of the Government of Japan, with additional support from Cytori. The trial is sponsored by the lead institution, Nagoya University.

About ADRESU Investigators

The ADRESU trial is being led by Dr. Momokazu Gotoh at Nagoya University, Aichi, Japan. The other participating investigators and institutes include Dr. Kazutaka Narimoto at Kanazawa University Hospital (Ishikawa, Japan), Dr. Osamu Ishizuka at Shinshu University Hospital (Nagano, Japan) and Dr. Tomonori Yamanashi at Dokkyo Medical University (Tochigi, Japan).

About Male Stress Urinary Incontinence

Male stress urinary incontinence is a post-surgical complication of radical prostatectomy and surgeries for benign prostatic hyperplasia with limited treatment options, representing an unmet medical need. In 2016, the Ministry of Health, Labor and Welfare (MHLW) reported approximately 20,000 prostate cancer surgeries and 22,000 benign prostatic hyperplasia procedures performed at Diagnostic Procedure Combination (DPC) participating hospitals.

About Cytori Cell Therapy™

Cytori is developing cell therapies that harness the unique attributes of adipose-derived regenerative cells (ADRCs), which are living cells that are present in an adult human’s own adipose tissue.

Cytori Cell Therapy™ is a suspension of ADRCs that are manufactured from a single lipoaspirate (material removed via liposuction, a procedure in which fat is removed from under the skin by suction). The process concentrates ADRCs intended for autologous re-implantation subcutaneously into the digits. The resultant cell suspension contains critical cells naturally occurring in the patient’s own tissue. Preparation of autologous ADRCs for subcutaneous delivery involves no cell culture and can be prepared and re-implanted into the same patient within 4 hours

About Cytori Therapeutics, Inc.

Cytori is developing, manufacturing, and commercializing nanoparticle-delivered oncology drugs and autologous adipose-derived regenerative cell (ADRC) therapies within its Nanomedicine™ and Cell Therapy™ franchises, respectively. Cytori Nanomedicine™ is focused on the liposomal encapsulation of anti-neoplastic chemotherapy agents, which may enable the effective delivery of the agents to target sites while reducing systemic toxicity. The Cytori Nanomedicine™ product pipeline consists of ATI-0918 pegylated liposomal doxorubicin hydrochloride for breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s sarcoma, a complex/hybrid generic drug, and ATI-1123 patented albumin-stabilized pegylated liposomal docetaxel for multiple solid tumors. Cytori Cell Therapy™, prepared within several hours with the proprietary Celution® System and administered to the patient the same day, has been shown in preclinical and clinical studies to act principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care. For more information, visit http://www.cytori.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, without limitation, conduct of clinical trials involving our technology, clinical performance, product approvals and product reimbursement, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, inherent risk and uncertainty in the protection intellectual property rights, regulatory uncertainties, risks in the conduct of clinical trials, risks in the collection and results of clinical data, final clinical outcomes, dependence on third party performance, performance and acceptance of our products in the marketplace, as well as other risks and uncertainties described under the heading "Risk Factors" in Cytori's Securities and Exchange Commission Filings on Form 10-K and Form 10-Q. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

Investor Contact:

Tiago Girao
Cytori Therapeutics, Inc.
1-858-458-0900
mailto://[e-mail]

[KennyPro]

Positive news this morning! :::

Hide Abstracts
< Back to Headlines
Cytori Announces Japan Class III Medical Device Approval for Cell Therapy Product
7:30 AM ET, 12/03/2018 - GlobeNewswire
SAN DIEGO and TOKYO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics (NASDAQ: CYTX) (“Cytori” or the “Company”) today announced that the Company has received approval for the Celution Cell Therapy System consumable bundle in Japan as a Class III medical device. The Class III designation will allow Cytori to expand its current commercial efforts in Japan and provides a clear framework for future expanded regulatory claims and reimbursement under the November 2014 PMD Act.

Furthermore, Cytori announced today that the Company has successfully outsourced an important assembly portion of the production process for its Celution Cell Therapy consumables from San Diego, CA to Viant Medical in San Antonio, Texas. The first consumable lots following this new process were shipped to customers in November 2018.

“Obtaining Class III designation follows many months of constructive interaction with the Japanese Ministry of Health, Labour and Welfare following the approval of the 2014 PMD Act,” said Marc H. Hedrick, MD, President and Chief Executive Officer of Cytori Therapeutics. “This approval coupled with the outsourced production allows Cytori to meet forecasted product demand, particularly in Japan, and better prepares us for the data read out in our Japan ADRESU pivotal trial next year.”

In Japan, Class III and Class IV medical devices require the highest levels of safety and efficacy data In Japan. These devices are also required to have special controls. Other such examples of Class III medical devices include: hemodialysis equipment, artificial bones and joints, mechanical ventilation apparatus, and balloon catheters.

Cytori currently has a fully functional logistics, sales and marketing team in Japan dedicated to commercialization of the Celution Cell Therapy System. Cytori is forecasting double digit growth in consumable utilization in Japan for 2018. Prior to the class III approval, Cytori has been selling the Celution technology mostly for aesthetic and orthopedic indications under a Class I designation.

ADRESU is an investigator-initiated, multicenter, 45 patient, open-label, single arm clinical trial of Cytori’s ECCI-50 cellular therapeutic, comprised of Celution®-prepared autologous Adipose Derived Regenerative Cells (ADRCs) and Adipose Cells for men with stress urinary incontinence as a complication of prostate intervention. A total of 45 patients, all treated in Japan, were enrolled in this potential approval trial. One-year data readout from ADRESU is anticipated in the first half of 2019.

The ADRESU trial was based on a promising pilot trial with short-term data of 11 patients published in the International Journal of Urology in 2014 and long-term data of 14 patients presented at the International Continence Society in 2017, which “demonstrated that transurethral injection of autologous ADRCs can be a safe and effective treatment modality for postprostatectomy incontinence”. Details of the ADRESU protocol and trial can be found on BMC Urology, clinicaltrials.gov and the University Hospital Medical Information Network website.

The primary endpoint for the ADRESU trial is the percentage of patients who experience greater than 50% reduction in urinary leakage volume from baseline (as measured by the weight of unintended urinary leakage over 24 hours) at 52 weeks after treatment. A number of other key secondary endpoints are also being assessed. If the primary endpoint is successfully achieved, the data may be used to seek approval of ECCI-50 for this indication.

The trial costs are substantially supported by the Japan Agency for Medical Research and Development, an independent administrative agency of the Government of Japan, with additional support from Cytori. The trial is sponsored by the lead institution, Nagoya University.

About ADRESU InvestigatorsThe ADRESU trial is being led by Dr. Momokazu Gotoh at Nagoya University, Aichi, Japan. The other participating investigators and institutes include Dr. Kazutaka Narimoto at Kanazawa University Hospital (Ishikawa, Japan), Dr. Osamu Ishizuka at Shinshu University Hospital (Nagano, Japan) and Dr. Tomonori Yamanashi at Dokkyo Medical University (Tochigi, Japan).

About Male Stress Urinary IncontinenceMale stress urinary incontinence is a post-surgical complication of radical prostatectomy and surgeries for benign prostatic hyperplasia with limited treatment options, representing an unmet medical need. In 2016, the Ministry of Health, Labor and Welfare (MHLW) reported approximately 20,000 prostate cancer surgeries and 22,000 benign prostatic hyperplasia procedures performed at Diagnostic Procedure Combination (DPC) participating hospitals.

About Cytori Cell Therapy™Cytori is developing cell therapies that harness the unique attributes of adipose-derived regenerative cells (ADRCs), which are living cells that are present in an adult human’s own adipose tissue.

Cytori Cell Therapy™ is a suspension of ADRCs that are manufactured from a single lipoaspirate (material removed via liposuction, a procedure in which fat is removed from under the skin by suction). The process concentrates ADRCs intended for autologous re-implantation subcutaneously into the digits. The resultant cell suspension contains critical cells naturally occurring in the patient’s own tissue. Preparation of autologous ADRCs for subcutaneous delivery involves no cell culture and can be prepared and re-implanted into the same patient within 4 hours

About Cytori Therapeutics, Inc.Cytori is developing, manufacturing, and commercializing nanoparticle-delivered oncology drugs and autologous adipose-derived regenerative cell (ADRC) therapies within its Nanomedicine™ and Cell Therapy™ franchises, respectively. Cytori Nanomedicine™ is focused on the liposomal encapsulation of anti-neoplastic chemotherapy agents, which may enable the effective delivery of the agents to target sites while reducing systemic toxicity. The Cytori Nanomedicine™ product pipeline consists of ATI-0918 pegylated liposomal doxorubicin hydrochloride for breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s sarcoma, a complex/hybrid generic drug, and ATI-1123 patented albumin-stabilized pegylated liposomal docetaxel for multiple solid tumors. Cytori Cell Therapy™, prepared within several hours with the proprietary Celution® System and administered to the patient the same day, has been shown in preclinical and clinical studies to act principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care. For more information, visit www.cytori.com.

Cautionary Statement Regarding Forward-Looking StatementsThis press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, without limitation, conduct of clinical trials involving our technology, clinical performance, product approvals and product reimbursement, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, inherent risk and uncertainty in the protection intellectual property rights, regulatory uncertainties, risks in the conduct of clinical trials, risks in the collection and results of clinical data, final clinical outcomes, dependence on third party performance, performance and acceptance of our products in the marketplace, as well as other risks and uncertainties described under the heading "Risk Factors" in Cytori's Securities and Exchange Commission Filings on Form 10-K and Form 10-Q. We assume no responsibilit

[KennyPro]

Wasn't too long ago this was trading at almost 20.00 a share....WTF? These guys need to step things up or sell the company!

[cabir]

Whay we still down at .3 ??!!
And not moove up!!!??

[KennyPro]

Hoping to see some encouraging information tomorrow with the Quarterly EOD.

[phil anthropist]

Fingers crossed on this one. Sold out some at a crummy 68% loss, needed to move dead money to something else. Ouch. Still think its a good company but SP is depressing. I'm sure executive of CYTX are knee deep in trying to stabilize. Good luck guys. I'm still in and hopeful.

[Paulness]

NEWS -- Cytori to Webcast Third Quarter Financial Results on November 14

Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its third quarter financial results and business update on Wednesday, November 14, 2018 at 5:30 PM Eastern Time.

The dial-in information is as follows:
Dial-In Number: +1.877.402.3914
Conference ID: 9699923

Prior to the webcast at approximately 4:30 PM Eastern Time on November 14, Cytori will issue its third quarter earnings release which will review Cytori’s third quarter and year-to-date performance. The webcast will be available both live and by replay two hours after the call in the “Webcasts” section of the company’s investor relations website.

About Cytori Therapeutics, Inc.

Cytori is developing, manufacturing, and commercializing nanoparticle-delivered oncology drugs and autologous adipose-derived regenerative cell (ADRC) therapies within its Nanomedicine™ and Cell Therapy™ franchises, respectively. Cytori Nanomedicine™ is focused on the liposomal encapsulation of anti-neoplastic chemotherapy agents, which may enable the effective delivery of the agents to target sites while reducing systemic toxicity. The Cytori Nanomedicine™ product pipeline consists of ATI-0918 pegylated liposomal doxorubicin hydrochloride for breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s sarcoma, a complex/hybrid generic drug, and ATI-1123 patented albumin-stabilized pegylated liposomal docetaxel for multiple solid tumors. Cytori Cell Therapy™, prepared within several hours with the proprietary Celution® System and administered to the patient the same day, has been shown in preclinical and clinical studies to act principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care. For more information, visit http://www.cytori.com.

Cytori Therapeutics, Inc.
Tiago Girao, 1.858.458.0900
mailto://[e-mail]

[PePe Le Profit]

Bouncing off the lows here! Could be last chance for anything under .36 today...

[PePe Le Profit]

Just a little lunch time dip....and back up we go!

[KennyPro]

HMMM? Maybe news coming?...I hope so. This could get really interesting quickly.

**** Could just be Lincoln Park buying shares?...

[PePe Le Profit]

MONSTER MOVE must be coming!!

[PePe Le Profit]

500k+ shares traded in first 30 min

[PePe Le Profit]

Anyone else seeing this? We are starting to move here!

[PePe Le Profit]

More large trades coming in. Nice volume out the gate today!

[PePe Le Profit]

Wow 52k share purchase @ 9:30 sharp!

[PePe Le Profit]

It’s bulging at the seams ready to blow the roof off.

[PePe Le Profit]

I’d imagine that royalty may help the earnings report? Yes?

[PePe Le Profit]

Breaking out above the .35 mark. I like what I see so far!

[phil anthropist]

Hard to figure CYTX out. News of a big royalty didn't help price. Down over 70% now. OUCH! Had to take some off the table, lick my wounds and move on. Still holding small position, hoping for green someday.

No opinion here, just venting. GL CYTX, let's turn things around.

[PePe Le Profit]

Perfect response. Grabbed a starter pack here.

[PePe Le Profit]

What’s going on here? This seems to have bottomed out .34 x .35 for almost a week now?

[Paulness]

NEWS -- Cytori Therapeutics Announces Receipt of Puregraft® Royalty Milestone

Date: 10/30/2018 @ 9:28AM
Source : GlobeNewswire Inc.

Cytori Therapeutics, Inc. (Nasdaq: CYTX) announced today it has received a milestone payment of $1.0 million from Bimini Technologies, LLC (Bimini). The payment is a result of Bimini achieving the first $10.0 million in gross profits for previous divestiture of the Puregraft® product line.

In 2013, Cytori entered into a Sale and Exclusive License/Supply Agreement with Bimini, pursuant to which Cytori sold to Bimini selected assets relating to Cytori’s Puregraft® product line, a series of standalone fat transplantation products that were developed to improve the predictability of outcomes for autologous fat grafting and aesthetic body contouring.

Bimini may also be obligated to make certain additional milestone payments to Cytori (in an aggregate amount of up to $10.0 million), contingent upon future achievement of certain milestones relating to Bimini’s gross profits from sales of the Puregraft products. The aggregate value of the consideration paid by Bimini to Cytori at the execution of the agreement in July 2013 was $5.0 million.

About Cytori Therapeutics

Cytori is developing, manufacturing, and commercializing nanoparticle-delivered oncology drugs and autologous adipose-derived regenerative cell (ADRC) therapies within its Nanomedicine™ and Cell Therapy™ franchises, respectively. Cytori Nanomedicine™ is focused on the liposomal encapsulation of anti-neoplastic chemotherapy agents, which may enable the effective delivery of the agents to target sites while reducing systemic toxicity. The Cytori Nanomedicine™ product pipeline consists of ATI-0918 pegylated liposomal doxorubicin hydrochloride for breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s sarcoma, a complex/hybrid generic drug, and ATI-1123 patented albumin-stabilized pegylated liposomal docetaxel for multiple solid tumors. Cytori Cell Therapy™, prepared within several hours with the proprietary Celution® System and administered to the patient the same day, has been shown in preclinical and clinical studies to act principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care. For more information, visit http://www.cytori.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements contained in this release, other than statements of historical fact, constitute “forward-looking statements.” The words "expects," "believes," "potential," "possibly," "estimates," "may," "could" and "intends," as well as similar expressions, are intended to identify forward-looking statements. These forward-looking statements do not constitute guarantees of future performance. Investors are cautioned that statements which are not strictly historical statements, including, without limitation, statements regarding the future achievement of milestones and any associated payments. Forward looking statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Please refer to the risk factors contained in Cytori’s Securities and Exchange Commission filings available at www.sec.gov, including without limitation, the preliminary prospectus relating to the rights offering and Cytori’s most recent reports on Forms 10-K, 10-Q and 8-K. These forward-looking statements speak only as of the date made. Cytori assumes no obligation or undertaking to update or revise any forward-looking statements contained herein to reflect any changes in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Cytori Therapeutics, Inc.
Tiago Girao, +1 [phone]
mailto://[e-mail]

[KennyPro]

We are going to need volume increasing news before we get a BOOOM! Good Opportunity to add to ones position here. I see it as a 50/50 investment. It will either get diluted to crap or will be an easy 5x's money. Could go either way but I have been in and buying when I can. I am expecting a nice payday here but it will be a long proposition IMO. People looking for instant gratification might need to look elsewhere?

[cabir]

I feel its Boooom today!!!

[PolishPowerplayer]

https://quotes.wsj.com/CYTX/research-ratings The consensus is a low of 5 bucks a share. Some analysts have this @ $12.00 I'd be very happy with 3.00.

[KennyPro]

And since they are not allowed to own more than a small % ( i think it was 4% ) of shares I am guessing they all figure by the time they buy their max number of shares the PPS will be much higher.

[tmp118]

At today’s prices that’s over 12 million shares

[tmp118]

Lincoln Park Capital Private Equity Fund Agrees to Buy up to $5 Million of Cytori Therapeutics Stock

9/21/18, 4:55 PM
04:55 PM EDT, 09/21/2018 (MT Newswires) -- Cytori Therapeutics (CYTX) late Friday said a Chicago-area private-equity and venture-capital firm has agreed to buy up $5 million of the company's sock from time to time.

Under terms of the purchase agreement, Lincoln Park Capital Fund is limited to buying no more than 250,000 Cytori shares per day and spending no more than $1 million daily on the company's shares. Lincoln Park also cannot buy Cytori stock during consecutive trading sessions and it is limited to owning no more than 4.99% of its outstanding stock.

Lincoln Park also will pay a $100,000 commitment fee to the company within five days of the purchase agreement becoming effective and it has agreed to an initial purchase of 380,000 shares priced at either the prior day's closing price or the 10-day average closing price, which ever is lower, according to a regulatory filing detailing the agreement.

[fares99]

I have watched this for years. It was my first stock that I thought had a chance. No matter what they release like clockwork, Price would bounce a little and goes down always. Then without a doubt the do a reverse split. wash rinse repeat. Been shorting now because why fight it.

[KennyPro]

HMMMMM, Well these guys are buying a bucket full of shares. Are they idiots? No They are not. Most Analysts have this up over 8 dollars a share. I think the company is very short on cash but close to some major developments. Don't listen to the shorts. People are putting big money into this company. Are You?....Me personally? I am buying when cash allows. Good luck whatever side you are betting on. It surely could go either way but I see good things happening here and in my portfolio. This may yet go lower with the short pressure, I will be buying if it does and be very happy if and WHEN it recovers.

[agorich]

What do you think about that S-1 they just released?

[fares99]

Dont get caught with this one. Watching this for years continuous down fall and reverse splits. Short it

[Chappy86]

You know they been working all day to unload those .42's so do it and get it over with and we can move up. SHeesh

[Chappy86]

Agreed and thanks for the response.

[KennyPro]

They are supposed to " facilitate trading "...nowadays all they do is manipulate and ruin the good orderly flow of trades and PPS. Mostly computer models and it ought to be stopped.

[Chappy86]

MM manipulation on this one is over the top.